Retatrutide: The Triple-Action Drug That’s Turning Heads in Obesity Research

If you’ve been paying attention to the latest in metabolic medicine, you’ve probably heard a buzz around retatrutide. Even though it’s still an investigational drug, meaning it isn’t approved yet and is only being studied in clinical trials, researchers and clinicians are excited about what it might do.

It’s a new kind of treatment that goes beyond earlier weight-loss medications and could change how we think about chronic metabolic conditions.

So What Is Retatrutide?

Retatrutide is an engineered peptide that works a bit differently than older drugs like semaglutide or tirzepatide. Rather than just targeting one hormone receptor, it activates three different hormone pathways at once: glucose-dependent insulinotropic polypeptide (GIP) receptors, glucagon-like peptide-1 (GLP-1) receptors, and glucagon receptors. This triple mechanism is why scientists sometimes call it a triple agonist.

Most current weight-loss drugs focus on appetite reduction and glucose regulation. Retatrutide still does that, but the added action on glucagon receptors may help increase energy expenditure and metabolic flexibility, meaning it could have a more powerful overall effect on body composition and metabolic health.

Right now, the medicine is being studied in Phase 3 trials as part of the TRIUMPH clinical program, which includes people with obesity and related conditions like type 2 diabetes, sleep apnea, knee osteoarthritis, and metabolic liver disease.

What the Research Shows So Far

Most of what we know about retatrutide comes from

Phase 2 and early Phase 3 trial data.

In a Phase 2 clinical trial published in The New England Journal of Medicine, adults with obesity (but no diabetes) were given weekly injections of retatrutide in different doses. After 48 weeks, participants on the highest dose (12 milligrams) experienced an average weight loss of about 24.2 percent of their body weight, which is huge compared with other medications in this space.

Beyond just weight loss, the study showed improvements in cardiometabolic markers such as blood pressure, cholesterol, and insulin sensitivity. That means retatrutide’s effects weren’t limited to the scale, metabolic health metrics shifted in favorable directions too.

Another Phase 2 substudy focused specifically on participants with metabolic dysfunction-associated steatotic liver disease (MASLD), showing dramatic reductions in liver fat, over 80 percent for higher doses after 24 weeks. That’s not only compelling for obesity treatment but also for liver health, which currently lacks effective drug therapies.

Early Phase 3 topline results presented by the drug’s developer, Eli Lilly and Company, suggest even stronger outcomes. In the TRIUMPH-4 trial, adults with obesity and knee osteoarthritis who completed treatment over about 68 weeks experienced an average weight loss of 28.7 percent with the highest doses. Some participants lost more than 70 pounds on average, and many saw meaningful knee pain relief, likely because of the weight reduction and improved physical function.

Why Retatrutide Might Stand Out

There are a few reasons doctors and researchers are watching retatrutide closely:

It’s targeting more than one hormonal pathway. 

Many current medications focus on GLP-1 alone, or GLP-1 plus GIP combined. Retatrutide’s triple-receptor activity may offer a broader metabolic impact, not only helping with appetite and glucose regulation but also potentially boosting energy expenditure and fat metabolism.

Clinical results are beyond

what we’ve seen before

The weight-loss percentages reported in phase 2 and early phase 3 trials approach figures often only seen with surgical procedures, and they come from a once-weekly injection. That could make retatrutide a revolutionary non-surgical option for people with severe obesity.

It plays into broader metabolic health

Retatrutide’s effects on liver fat, lipids, blood pressure, and insulin sensitivity suggest it isn’t just about weight loss. Those changes could help reduce long-term risks tied to metabolic diseases, including type 2 diabetes and cardiovascular complications.

All that said, we should be clear: retatrutide isn’t approved yet. Scientists are still collecting data and assessing long-term safety. That’s why it’s only available through clinical trials for now.

The Bottom Line

Retatrutide represents one of the most exciting developments in obesity and metabolic medicine in recent years. Its unique triple-agonist mechanism and early clinical trial data suggest it may support significant, sustained improvements in weight loss and broader metabolic health. Ongoing Phase 3 research will continue to clarify its long-term efficacy and safety across more diverse populations, but current findings highlight strong investigational potential.

At Mana Loa Health, we emphasize a strategic, stepwise approach to GLP-1 therapy rather than starting with the most advanced options first. GLP-1 medications can become less effective over time, especially when used without foundational metabolic support, which is why thoughtful progression matters for long-term success.

Many patients experience excellent outcomes on established therapies such as semaglutide, with some achieving 70+ pounds of weight loss when treatment is paired with nutrition, strength training, and lifestyle optimization. For many individuals, there is no clinical reason to begin with a triple-agonist therapy if they have not yet responded to or maximized first-line GLP-1 options.

This structured approach allows patients to preserve future therapeutic options, optimize long-term metabolic response, and build sustainable habits alongside medication support. Retatrutide remains a promising investigational tool, but its role in care should be considered within a broader, individualized metabolic strategy rather than as a first-line starting point.

Currently treating patients located in:

Colorado, Florida, Hawaii, and Washington!

Click the link to schedule a consultation today!

https://mana-loa.clientsecure.me

-The Mana Loa Health Team

ClinicalTrials.gov. Ongoing studies evaluating retatrutide in obesity and related conditions.https://clinicaltrials.gov

Eli Lilly and Company. 2023. Lilly’s phase 2 retatrutide results published in The New England Journal of Medicine.https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-retatrutide-results-published-new-england-journal

Eli Lilly and Company. 2024. What to know about retatrutide and the TRIUMPH phase 3 clinical program.https://www.lilly.com/news/stories/what-to-know-about-retatrutide

Jastreboff, A. M., et al. 2023. Triple hormone receptor agonist retatrutide for obesity. The New England Journal of Medicine.https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

Newsome, P. N., et al. 2024. Retatrutide for metabolic dysfunction associated steatotic liver disease. Nature Medicine.https://www.nature.com/articles/s41591-024-03018-2

Patient safety is Mana Loa Health's top priority. The information discussed on this blog is not intended to recommend the self management of health problems or wellness. It is not intended to endorse or recommend any particular type of medical treatment or advice. The information provided on this website is for informational purposes and not a substitute for professional medical advice, diagnosis, or treatment. If you have questions or concerns about your health, please talk to your healthcare provider. No information contained on this blog should be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider.